Truist Financial Cuts GoodRx (NASDAQ:GDRX) Price Target to $5.50

GoodRx (NASDAQ:GDRX) had its price objective trimmed by Truist Financial from $6.50 to $5.50 in a report published on Thursday,Benzinga reports. The brokerage currently has a hold rating on the stock.

GDRX has been the topic of a number of other reports. Wells Fargo & Company dropped their price objective on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Morgan Stanley cut their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Citigroup lowered their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, KeyCorp cut their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx presently has an average rating of “Moderate Buy” and a consensus price target of $7.93.

GoodRx Trading Up 2.3 %

NASDAQ GDRX opened at $4.42 on Thursday. GoodRx has a 52 week low of $3.82 and a 52 week high of $9.26. The business has a 50 day moving average price of $4.65 and a 200-day moving average price of $5.07. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -147.33, a P/E/G ratio of 2.46 and a beta of 1.25.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in the business. Total Wealth Planning & Management Inc. bought a new stake in GoodRx in the fourth quarter worth about $68,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of GoodRx by 70.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 149,945 shares of the company’s stock worth $697,000 after purchasing an additional 61,924 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of GoodRx by 69.1% in the 4th quarter. Two Sigma Advisers LP now owns 754,000 shares of the company’s stock worth $3,506,000 after purchasing an additional 308,000 shares during the period. Two Sigma Investments LP lifted its stake in GoodRx by 98.1% in the fourth quarter. Two Sigma Investments LP now owns 722,374 shares of the company’s stock valued at $3,359,000 after purchasing an additional 357,674 shares during the last quarter. Finally, State of Wyoming grew its holdings in GoodRx by 76.2% during the fourth quarter. State of Wyoming now owns 67,290 shares of the company’s stock valued at $313,000 after purchasing an additional 29,100 shares during the period. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.